Clinical trials: Locally Advanced Head and Neck Carcinoma
Oral Cancer
Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer
The goal of this observational study is to investigate the effectiveness of neoadjuvant chemoimmunotherapy (NACI) regimens in treating advanced oral squamous cell carcinoma (OSCC) patients.
- Trial name
- HNC-SYSU-005 (NCT06143761)
- Testing
- PD-1 inhibitor+carboplatin+albumin-bound paclitaxel
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Squamous Cell Carcinoma, Head and Neck Cancer
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
Whether low-dose radiation in addition to Taxotere and Erbitux improves the response rate of patients with recurrent unresectable head and neck squamous cell carcinoma.
- Conditions
- Squamous Cell Carcinoma, Head and Neck Cancer, Recurrent Disease
- Trial name
- NCT01794845
- Testing
- Erbitux, Taxotere, Low Dose Fractionated Radiation Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Miami
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Esophageal Squamous Cell Carcinoma (ESCC), Infiltration
Infiltration Pattern of Locally Advanced ESCC
Prospectively collect the pathological records of ESCC patients, and analyse the infiltration pattern of ESCC.
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Infiltration, Tumour
- Trial name
- NCT07567716
- Testing
- Esophagectomy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Chest Hospital
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult…
- Trial name
- TRIDENT-1 (NCT03093116)
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 165 sites in United States, Australia and 17 more
- Volunteers
- 500 people
- Sponsor
- Turning Point Therapeutics, Inc.
Tongue Neoplasms, Squamous Cell Carcinoma
Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue
Patients enrolled for the study, who are eligible for NACT, will undergo a pre-treatment workup comprising of Evaluation Under Anesthesia (EUA) for tumor Mapping and tissue biopsy along with a PET-CT scan.
- Conditions
- Tongue Neoplasms, Squamous Cell Carcinoma, Anterior Tongue Squamous Cell Carcinoma
- Trial name
- NCT02985255
- Testing
- Docetaxel, Cisplatin, 5FU
- Where
- India
- Volunteers
- 30 people
- Sponsor
- HealthCare Global Enterprise Ltd.
Oral Squamous Cell Carcinoma, Neoadjuvant Chemotherapy
Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma
Backgrounds Squamous cell carcinoma of the oral cancer (OSCC) is the sixth most common malignancy. Surgery is the mainstay of treatment for oral cancers.
- Trial name
- NCT04137627
- Testing
- Melatonin 20 MG Oral Capsule
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Universitas Indonesia
Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck, LA SCCHN
A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This prospective, observational, multicentre, post marketing surveillance study will collect safety and efficacy information on patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN) treated with…
- Trial name
- PMS LAD SCCHN (NCT01303237)
- Testing
- Cetuximab + RT
- Where
- 25 sites in India
- Volunteers
- 88 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Head and Neck Neoplasm, Squamous Cell Carcinoma
A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer
Radiotherapy plus Single-Agent Chemotherapy/Radiosensitization. Irradiation of tumor and involved nodes using 4-6 MV photons (brachytherapy allowed to boost primary tumor; electrons allowed to boost posterior neck and massive…
- Trial name
- NCT00001442
- Testing
- paclitaxel concurrent with radiation therapy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)
Early Metabolic Response in Locally Advanced Esophageal Cancer Undergoing Induction Chemoradiotherapy
Early metabolic response evaluation may predict clinical and histopathological response after neoadjuvant chemotherapy. Its value in neoadjuvant chemoradiotherapy (CRT) is unknown.
- Trial name
- NCT01269970
- Testing
- 18-FDG-PET-CT
- Where
- Belgium
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Drug Use for Unapproved Schedule
EBV Positive Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug
PCR-DNA of EBV test is a good prognostic indicator for survival after treatment (report: Prognostic Impact of Plasma, Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation…
- Trial name
- NCT03656965
- Testing
- Acyclovir 800 MG, Radiotherapy and chemotherapy
- Where
- Kuwait
- Volunteers
- 50 people
- Sponsor
- Kuwait Cancer Control Center
Locally Advanced Head and Neck Cancer
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer
Background: Locally advanced head and neck cancer (HNC) is a challenge as, in spite of initial good control with chemoradiation, the majority of patients fails systemically.
- Trial name
- NCT03532737
- Testing
- Pembrolizumab
- Where
- Kuwait
- Volunteers
- 50 people
- Sponsor
- Kuwait Cancer Control Center
Head and Neck Cancer
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544414
- Testing
- cisplatin, docetaxel, fluorouracil
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Advanced or Metastatic Solid Tumors
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors To evaluate the safety and tolerability of naporafenib administered with trametinib in…
- Trial name
- SEACRAFT-1 (NCT05907304)
- Testing
- Naporafenib, Trametinib
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- Erasca, Inc.
Nasopharyngeal Carcinoma, PET/MR
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT03657017
- Testing
- PET/MR
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhejiang Cancer Hospital
Carcinoma, Nasopharyngeal
Randomized Trial to Evaluate Accelerated Radiotherapy in Locally Advanced Carcinoma of Nasopharynx
The present study is designed as a two arm randomized trial to evaluate the impact of accelerated radiotherapy delivered by image guided radiotherapy with rapid arc technique in carcinoma nasopharynx.
- Trial name
- EARN (NCT04538547)
- Testing
- Accelerated Radiotherapy, Non Accelerated Radiotherapy
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Head and Neck Cancer, Oral Cavity Cancer
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate if the addition of valproic acid to standard platinum-based chemoradiation as definitive treatment of locally advanced Head and Neck squamous cell carcinoma can improve treatment outcomes…
- Conditions
- Head and Neck Cancer, Oral Cavity Cancer, Oropharyngeal Cancer
- Trial name
- NCT01695122
- Testing
- Valproic Acid
- Where
- Brazil
- Volunteers
- 14 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma
Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
This phase II trial studies how well docetaxel, cisplatin and fluorouracil work in treating patients with previously untreated stage II-IV nasal cavity and/or paranasal sinus cancer.
- Conditions
- Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma, Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8
- Trial name
- NCT00707473
- Testing
- Carboplatin, Chemoradiotherapy, Cisplatin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center